Cambridge Investment Research Advisors Inc. Grows Stake in Senseonics Holdings, Inc. (NYSE:SENS)

Cambridge Investment Research Advisors Inc. boosted its position in Senseonics Holdings, Inc. (NYSE:SENS) by 679.9% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 289,919 shares of the company’s stock after purchasing an additional 252,745 shares during the period. Cambridge Investment Research Advisors Inc.’s holdings in Senseonics were worth $190,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Raymond James Financial Inc. acquired a new position in Senseonics in the fourth quarter valued at $26,000. HighTower Advisors LLC bought a new stake in Senseonics in the fourth quarter valued at about $32,000. Two Sigma Investments LP acquired a new position in Senseonics in the fourth quarter valued at approximately $36,000. Northern Trust Corp boosted its stake in Senseonics by 11.2% in the fourth quarter. Northern Trust Corp now owns 1,194,960 shares of the company’s stock valued at $625,000 after acquiring an additional 120,441 shares during the period. Finally, Beck Mack & Oliver LLC acquired a new position in shares of Senseonics during the fourth quarter worth approximately $79,000. Institutional investors and hedge funds own 12.36% of the company’s stock.

Senseonics Trading Down 0.8%

NYSE SENS opened at $0.49 on Tuesday. The company has a current ratio of 2.47, a quick ratio of 2.38 and a debt-to-equity ratio of 59.17. The company has a market capitalization of $322.46 million, a PE ratio of -3.79 and a beta of 0.92. Senseonics Holdings, Inc. has a 1-year low of $0.25 and a 1-year high of $1.40. The firm’s fifty day simple moving average is $0.53 and its 200-day simple moving average is $0.68.

Wall Street Analysts Forecast Growth

SENS has been the subject of a number of research analyst reports. Wall Street Zen upgraded Senseonics to a “sell” rating in a research report on Monday, May 12th. Mizuho began coverage on shares of Senseonics in a research note on Thursday, April 10th. They set an “outperform” rating and a $2.00 target price on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $1.40 target price (up from $1.10) on shares of Senseonics in a research note on Tuesday, July 8th.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.